InflaRx reported an EPS surprise of +2.86% and a revenue surprise of -117.03% for the quarter ended December 2025. The small earnings beat versus a massive revenue miss creates uncertainty for the stock and could move the share price modestly (roughly 1–3%) as investors assess whether the revenue shortfall reflects commercial issues, timing effects, or one‑off items; monitoring guidance and pipeline/clinical milestones is key.
InflaRx reported an EPS surprise of +2.86% and a revenue surprise of -117.03% for the quarter ended December 2025. The small earnings beat versus a massive revenue miss creates uncertainty for the stock and could move the share price modestly (roughly 1–3%) as investors assess whether the revenue shortfall reflects commercial issues, timing effects, or one‑off items; monitoring guidance and pipeline/clinical milestones is key.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mixed
Sentiment Score
-0.05
Ticker Sentiment
